AS 101

Drug Profile

AS 101

Alternative Names: AS101; CB-06-02; IVAX-Q-101; IVX-Q-101; Ossirene; WAX-120337

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bar-Ilan University
  • Developer BioMAS; Cassiopea
  • Class Antineoplastics; Antipsoriatics; Antivirals; Infertility therapies; Nitrogen compounds; Organometallic compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunomodulators; Integrin alpha4beta1 antagonists; Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Age-related macular degeneration; Genital warts
  • Preclinical Female infertility; Male infertility
  • Discontinued Acute myeloid leukaemia; Atopic dermatitis; Chemotherapy-induced damage; HIV infections; Myelodysplastic syndromes; Neurological disorders; Psoriasis; Thrombocytopenia

Most Recent Events

  • 23 Jul 2018 Cassiopea intends to launch CB 06-02 in 2022
  • 19 Jul 2018 Efficacy and adverse events data from a phase I/II trial in Genital warts released by Cassiopoea
  • 19 Jul 2018 Efficacy and adverse events data from a phase II in Genital warts released by Cassiopea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top